Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10831	Companies
235059	Keywords
163929	Articles
125833	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 06/06/2025 at 15:00, 1 year 2 months ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health's CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025 to discuss the company's orphan disease development programs

Pharmaceuticals Jaguar Health Lisa Conte Virtual Fireside Chat Orphan Disease Development
BRIEF

published on 05/21/2025 at 14:05, 1 year 2 months ago

Jaguar Health réalise une offre publique d'achat directe enregistrée de 1,5 million de dollars

Nasdaq Placement Privé Jaguar Health Actions Ordinaires Offre Directe
BRIEF

published on 05/21/2025 at 14:05, 1 year 2 months ago

Jaguar Health Conducts $1.5M Registered Direct Offering

Private Placement Nasdaq Jaguar Health Common Stock Direct Offering
PRESS RELEASE

published on 05/21/2025 at 14:00, 1 year 2 months ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces purchase of 246,306 shares of common stock at $6.09 per share in a registered direct offering. H.C. Wainwright & Co. serves as exclusive placement agent

Shares Stock Purchase Jaguar Health H.C. Wainwright & Co. Direct Offering
BRIEF

published on 05/20/2025 at 15:20, 1 year 2 months ago

Jaguar Health lance un essai de phase 2 pour le Crofelemer chez les patients pédiatriques atteints de MVID

Crofelemer Jaguar Health Essai De Phase 2 MVID Traitement Pédiatrique
BRIEF

published on 05/20/2025 at 15:20, 1 year 2 months ago

Jaguar Health Begins Phase 2 Trial for Crofelemer in Pediatric MVID Patients

Crofelemer Jaguar Health Phase 2 Trial MVID Pediatric Treatment
PRESS RELEASE

published on 05/20/2025 at 15:15, 1 year 2 months ago

First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Jaguar Health's crofelemer shows promise in reducing total parenteral support in pediatric MVID patient. Ongoing trials and future expectations discussed

Crofelemer Clinical Trials Jaguar Health Pediatric MVID Total Parenteral Support
BRIEF

published on 05/19/2025 at 16:42, 1 year 2 months ago

Jaguar Health Inc. reçoit une note d'achat de First Berlin Equity Research

Crofelemer Jaguar Health Approbation De La FDA Acheter Une Note Potentiel De Croissance
BRIEF

published on 05/19/2025 at 16:42, 1 year 2 months ago

Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

Crofelemer FDA Approval BUY Rating Jaguar Health Growth Potential
PRESS RELEASE

published on 05/19/2025 at 16:37, 1 year 2 months ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Jaguar Health Inc, recommending a Buy with USD 60.00 price target. Jaguar focuses on plant-based medicines for GI health challenges, with crofelemer as flagship product

Jaguar Health Inc First Berlin Equity Research BUY Rating Plant-based Medicines GI Health Challenges

Accesswire

Published on 08/13/2026 at 14:15, 6 minutes ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
Published on 08/13/2026 at 14:00, 21 minutes ago

AEONIAN Expands Koocanusa Copper Project to Approximately 412 Km(2); Fieldwork Underway Across Four New Target Areas
Published on 08/13/2026 at 14:00, 21 minutes ago

Adcore Reports Q2 2026 Results: Gross Margin Expands to 51% as Revenue Grows 10% to CAD$7.2 million and North America Rebounds 27% to CAD$1.5 million
Published on 08/13/2026 at 14:00, 21 minutes ago

GameSquare Appoints Tom Wild as Vice President of Creative Strategy for EMEA
Published on 08/13/2026 at 13:30, 51 minutes ago

ROK Resources Announces Normal Course Issuer Bid

View all ACCESSWIRE

EQS Group

Published on 08/13/2026 at 13:45, 35 minutes ago

REINET INVESTMENTS S.C.A. ANNOUNCES SHARE BUYBACK PROGRAMME
Published on 08/13/2026 at 13:27, 53 minutes ago

Original-Research: Grand City Properties SA (von First Berlin Equity Research GmbH): Kaufen
Published on 08/13/2026 at 13:15, 1 hour 5 minutes ago

DoGo Power Wins EUPD Research's 2026 Top Innovation Award in Europe
Published on 08/13/2026 at 11:54, 2 hours 26 minutes ago

25 Years Redcare Pharmacy: From a digital pioneer to Europe’s leading online pharmacy.
Published on 08/13/2026 at 11:52, 2 hours 28 minutes ago

Holding(s) in Company

Les Echos

Published on 08/11/2026 at 17:45, 1 day 20 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 20 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 20 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 20 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 2 days 20 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE